Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

LianBio to Start China Phase III Trial of Bile Cancer Drug

publication date: Nov 4, 2020

LianBio, a Shanghai-Princeton biotech, has been approved to start a Phase III trial of infigratinib in China. Infigratinib is a potential first-line treatment for locally advanced or metastatic unresectable cholangiocarcinoma (bile cancer) with FGFR2 gene fusions. It is one of two oncology candidates that LianBio in-licensed from BridgeBio three months ago in a $538 million agreement. Last week, LianBio raised $310 million in its first funding round to support China/Asia development of western drugs. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital